Trial Profile
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; GO 203 2c (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 09 Jan 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2023.
- 25 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.